What is the recommended treatment regimen for osteoporosis in adults?

Osteoporosis Treatment in Adults

For adults ≥40 years at high fracture risk, oral bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly) are the first-line treatment, strongly recommended over all other options including IV bisphosphonates, denosumab, teriparatide, and raloxifene. 1

Risk Stratification Framework

Treatment decisions must be guided by categorical fracture risk assessment, not simply BMD values alone:

Very High Risk (3-year fracture risk ≥10%)

• Anabolic agents are conditionally recommended as first-line therapy over antiresorptive drugs 1
• Options include teriparatide, abaloparatide, or romosozumab 1, 2
• This category includes patients with recent vertebral fractures, hip fracture with T-score ≤-2.5, or multiple fractures 2

High Risk

• Oral bisphosphonates remain the strongly recommended first-line choice based on safety, cost, and proven antifracture efficacy 3, 1
• High risk is defined as: history of osteoporotic fracture, T-score ≤-2.5 at hip or spine, FRAX 10-year major fracture risk ≥20%, or FRAX hip fracture risk ≥3% 1

Moderate Risk (3-year fracture risk >3%)

• Oral or IV bisphosphonates, denosumab, or PTH/PTHrP agents are all conditionally recommended 1
• Selection should prioritize adherence potential, GI tolerability, cost, and individual safety profile 1

Foundational Non-Pharmacologic Management

All patients require optimization before or concurrent with pharmacologic therapy:

• Calcium 1,000-1,200 mg/day (dietary plus supplements if needed) 3, 1
• Vitamin D 800-1,000 IU/day (target serum level ≥20 ng/mL) 3, 1
• Regular exercise combining balance training, resistance strengthening, and weight-bearing activity 1, 2
• Smoking cessation and alcohol limitation to ≤1-2 drinks/day 3, 1

Specific Pharmacologic Agents

Oral Bisphosphonates (First-Line for High Risk)

• Alendronate 70 mg once weekly or risedronate 35 mg once weekly 1, 2
• Ibandronate 150 mg monthly is an alternative 4
• Preferred due to strong antifracture efficacy, established safety profile, and low cost 3
• GI adverse effects (esophagitis, dyspepsia) may limit adherence 4, 1
• Must be taken on empty stomach with full glass of water, remaining upright for 30-60 minutes 5

IV Bisphosphonates (Second-Line)

• Zoledronic acid 5 mg once yearly 4, 1, 2
• Higher risk profile than oral bisphosphonates due to IV infusion requirements 3
• May cause acute-phase reaction (fever, myalgias, arthralgias) within first week, treatable with acetaminophen or ibuprofen 4, 1
• Useful when oral bisphosphonates are contraindicated or adherence is problematic 6

Denosumab (Alternative Antiresorptive)

• 60 mg subcutaneously every 6 months 4, 1, 2
• Conditionally recommended when bisphosphonates are unsuitable 1
• Critical warning: Discontinuation without transition to bisphosphonate therapy causes rapid rebound bone loss and high risk of multiple vertebral fractures 4, 1, 7
• Insufficient safety data in immunosuppressed patients 3, 1
• Sequential bisphosphonate therapy is mandatory upon stopping denosumab 1, 7

Anabolic Agents (Very High Risk First-Line)

• Teriparatide or abaloparatide administered daily subcutaneously 1, 2, 7
• Romosozumab provides dual anabolic/antiresorptive action 8, 2, 7
• Reserved for very high-risk patients due to cost and daily injection burden 3
• Sequential bisphosphonate therapy is required after discontinuation to prevent bone loss 1, 7
• Romosozumab has cardiovascular safety considerations that require evaluation 6

Raloxifene (Limited Role)

• Reserved for postmenopausal women when all other agents are inappropriate 3, 1
• Lacks adequate fracture data in high-risk populations and carries thrombotic risks 3
• Strong recommendation against using estrogen, estrogen+progestogen, or raloxifene as primary therapy in most women 1

Age-Specific Considerations

Adults ≥40 Years

• Treatment thresholds and agent selection follow the risk stratification above 1
• FRAX tool should be applied to estimate 10-year fracture probability 1

Adults <40 Years

• Low-risk individuals: calcium, vitamin D, and lifestyle optimization only—no pharmacologic therapy 3, 9, 1
• Moderate-to-high risk (history of osteoporotic fracture, Z-score <-3, or ≥10%/year bone loss): oral bisphosphonates conditionally recommended 3, 9, 1
• Use Z-scores (not T-scores); Z-score ≤-2.0 indicates low bone mass for age 1
• Strong recommendation against IV bisphosphonates in low-risk patients <40 years due to unnecessary harm 9, 1

Special Populations

Glucocorticoid-Induced Osteoporosis (GIOP)

• Screen all adults receiving ≥2.5 mg/day prednisone for >3 months within 6 months of initiation 3, 1
• For prednisone >7.5 mg/day, apply FRAX glucocorticoid dose-adjustment factor (multiply major fracture risk by 1.15, hip fracture risk by 1.2) 9, 1
• Oral bisphosphonates strongly recommended for high/very high risk 3, 1
• Treatment hierarchy if oral bisphosphonates unsuitable: IV bisphosphonates, then teriparatide, then denosumab 3, 9

Cancer Survivors (Aromatase Inhibitors, ADT)

• Offer bone-modifying agents when T-score ≤-2.5 or FRAX 10-year risk ≥20% for major fractures or ≥3% for hip fracture 4, 1
• Options include oral bisphosphonates, IV bisphosphonates, or denosumab at osteoporosis-approved doses 4, 1
• Denosumab 60 mg every 6 months has strongest fracture reduction evidence in this population 4
• Perform BMD assessment every 2 years (more frequently if near treatment thresholds) 4, 1

Treatment Monitoring

• Follow-up DXA BMD testing 1-5 years after initiating or changing therapy, tailored to clinical circumstances 1
• Routine BMD monitoring during first 5 years of pharmacologic treatment is NOT recommended 1
• Each facility must determine its precision error and calculate least significant change (LSC) for reliable interpretation 1
• Ideally perform follow-up DXA at same center using same scanner 1

Sequential Therapy Principle (Critical)

After stopping denosumab, romosozumab, or PTH/PTHrP agents, a bisphosphonate MUST be initiated to prevent rebound bone loss and vertebral fractures. 1, 7 This is the most common and dangerous pitfall in osteoporosis management—failure to transition off these agents appropriately markedly increases severe vertebral fracture risk 1.

Duration of Bisphosphonate Therapy

• Reassess ongoing need after 5 years of oral bisphosphonates or 3 years of IV zoledronic acid 5, 7
• Treatment may be interrupted in some patients with stabilized risk 7
• Progressive bone loss will recur slowly after bisphosphonate discontinuation 7
• Most patients require some form of long-term therapy once started 7

Common Pitfalls to Avoid

• Failing to transition patients off denosumab, romosozumab, or PTH/PTHrP to bisphosphonate causes severe rebound vertebral fractures 1, 7
• Relying solely on BMD without incorporating clinical risk factors misses high-risk patients 1
• FRAX underestimates fracture risk in patients on very high glucocorticoid doses (≥30 mg/day prednisone) 1
• Using IV bisphosphonates in low-risk patients <40 years exposes them to unnecessary adverse effects 1
• Prescribing denosumab to immunosuppressed patients lacks adequate safety data 3, 1
• Assuming normal BMD means cure—osteoporosis diagnosis persists even if subsequent T-scores rise above -2.5 5